Video

Observational data can’t answer question of inhibiting ankylosing spondylitis progression


 

REPORTING FROM THE EULAR 2018 CONGRESS

AMSTERDAM – The attempt to determine whether biologics such as tumor necrosis factor inhibitors (TNFi) inhibit progression of ankylosing spondylitis has been pursued with observational studies, but these types of studies will never definitively answer the question, according to Robert B.M. Landewé, MD, PhD, professor of rheumatology at the University of Amsterdam.

“The methodology is sensitive to a lot of measurement error, making the results spurious,” Dr. Landewé said in an interview, recapping remarks he made in a presentation at the European Congress of Rheumatology.

This was disappointing to many investigators, including several speaking in the same symposium where Dr. Landewé made his remarks. Randomized, controlled trials that employ serial radiographs to document changes in ankylosing spondylitis are expensive, making observational studies an attractive surrogate, but Dr. Landewé said such studies are associated with an inherent risk of residual confounding.

In addition, he believes the effect size of biologics on progression, if it exists at all, is likely to be subtle. In the observational studies that have concluded that there is protection, complicated statistical analyses have been typically employed to produce a significant finding.

Observational studies do have hypothesis-generating value, according to Dr. Landewé, but he cautioned that they produce “more questions than answers.” He also emphasized that the inflammation-related progression that leads to bone growth in ankylosing spondylitis is different than it is in the destructive inflammatory diseases, such as rheumatoid arthritis, where the issue is bone loss.


It is rational to assume that effective anti-inflammatory therapy would prevent progression of inflammatory diseases, but Dr. Landewé said in his presentation that this is the type of bias that undermines the value of observational studies for reaching objective conclusions. Unlike the results of a registered randomized, controlled trial, which will be known to be consistent or not with the underlying hypothesis, there is a strong risk that data in an observational study will be reworked until they produce the desired result.

Recommended Reading

FDA approves certolizumab label update for pregnancy, breastfeeding
MDedge Internal Medicine
Axial SpA disease activity remains mostly stable throughout pregnancy
MDedge Internal Medicine
TB in 2017: Good news and bad news
MDedge Internal Medicine
MACE risk similar across arthritis subtypes
MDedge Internal Medicine
Physical therapy, exercise still relevant for ankylosing spondylitis
MDedge Internal Medicine
Comorbid spondyloarthritis and fibromyalgia lower response to TNF inhibitors
MDedge Internal Medicine
Eye-opening findings cast spondyloarthritis in new light, expert says
MDedge Internal Medicine
Axial SpA diagnostic strategies need not be sex-specific
MDedge Internal Medicine
Ankylosing spondylitis diagnosis linked to self-harm attempts
MDedge Internal Medicine
TNF inhibitor may protect against axSpA sacroiliac joint progression
MDedge Internal Medicine